{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:31:53Z","timestamp":1792063913432,"version":"4.4.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>Anabolic androgenic steroids (AASs) are appearance and performance-enhancing drugs (APEDs) used in competitive athletics, in recreational sports, and by body-builders. The global lifetime prevalence of AASs abuse is 6.4% for males and 1.6% for women. Many AASs, often obtained from the internet and dubious sources, have not undergone proper testing and are consumed at extremely high doses and in irrational combinations, also along with other drugs. Controlled clinical trials investigating undesired side effects are lacking because ethical restrictions prevent exposing volunteers to potentially toxic regimens, obscuring a causal relationship between AASs abuse and possible sequelae. Because of the negative feedback in the regulation of the hypothalamic\u2013pituitary\u2013gonadal axis, in men AASs cause reversible suppression of spermatogenesis, testicular atrophy, infertility, and erectile dysfunction (anabolic steroid-induced hypogonadism). Should spermatogenesis not recover after AASs abuse, a pre-existing fertility disorder may have resurfaced. AASs frequently cause gynecomastia and acne. In women, AASs may disrupt ovarian function. Chronic strenuous physical activity leads to menstrual irregularities and, in severe cases, to the female athlete triad (low energy intake, menstrual disorders and low bone mass), making it difficult to disentangle the effects of sports and AASs. Acne, hirsutism and (irreversible) deepening of the voice are further consequences of AASs misuse. There is no evidence that AASs cause breast carcinoma. Detecting AASs misuse through the control network of the World Anti-Doping Agency (WADA) not only aims to guarantee fair conditions for athletes, but also to protect them from medical sequelae of AASs abuse.<\/jats:p>","DOI":"10.1530\/eje-15-0080","type":"journal-article","created":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T05:50:53Z","timestamp":1427262653000},"page":"R47-R58","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":198,"title":["MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions"],"prefix":"10.1093","volume":"173","author":[{"given":"Eberhard","family":"Nieschlag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Vorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2015070319494900000_173.2.R47.1","doi-asserted-by":"crossref","unstructured":"Sch\u00e4nzer W & Thevis M. Detection of illegal use of androgens and selective androgen receptor modulators. In Testosterone: Action, Deficiency, Substitution, 4th edn, ch 24, pp 517\u2013534. Eds E Nieschlag, HM Behre & S Nieschlag. Cambridge: Cambridge University Press, 2012","DOI":"10.1017\/CBO9781139003353.025"},{"key":"2015070319494900000_173.2.R47.2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.12.130"},{"key":"2015070319494900000_173.2.R47.3","doi-asserted-by":"crossref","unstructured":"Sagoe D Molde H Andreassen CS Torsheim T Pallesen S . The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of Epidemiology 2014 24 383\u2013398. (doi:10.1016\/j.annepidem.2014.01.009).","DOI":"10.1016\/j.annepidem.2014.01.009"},{"key":"2015070319494900000_173.2.R47.4","doi-asserted-by":"crossref","unstructured":"Nieschlag E Nieschlag S . Testosterone deficiency: a historical perspective. Asian Journal of Andrology 2014 16 161\u2013168. (doi:10.4103\/1008-682X.122358).","DOI":"10.4103\/1008-682X.122358"},{"key":"2015070319494900000_173.2.R47.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2014-093526"},{"key":"2015070319494900000_173.2.R47.6","doi-asserted-by":"crossref","unstructured":"Krug O Thomas A Walpurgis K Piper T Sigmund G Sch\u00e4nzer W Laussmann T Thevis M . Identification of black market products and potential doping agents in Germany 2010\u20132013. European Journal of Clinical Pharmacology 2014 70 1303\u20131311. (doi:10.1007\/s00228-014-1743-5).","DOI":"10.1007\/s00228-014-1743-5"},{"key":"2015070319494900000_173.2.R47.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.013"},{"key":"2015070319494900000_173.2.R47.8","doi-asserted-by":"crossref","unstructured":"Raschka C Chmiel C Preiss R Boos C . Recreational athletes and doping \u2013 a survey in 11 gyms in the area of Frankfurt\/Main. M\u00fcnchener Medizinische Wochenschrift 2013 155 (Suppl 2) 41\u201343.","DOI":"10.1007\/s15006-013-1052-4"},{"key":"2015070319494900000_173.2.R47.9","unstructured":"Brennan BP Kanayama G Pope HG Jr . Performance-enhancing drugs on the web: a growing public-health issue. American Journal on Addictions\/American Academy of Psychiatrists in Alcoholism and Addictions 2013 22 158\u2013161. (doi:10.1111\/j.1521-0391.2013.00311.x)."},{"key":"2015070319494900000_173.2.R47.10","doi-asserted-by":"crossref","unstructured":"Van Thuyne W Van Eenoo P Delbeke FT . Nutritional supplements: prevalence of use and contamination with doping agents. Nutrition Research Reviews 2006 19 147\u2013158. (doi:10.1079\/NRR2006122).","DOI":"10.1079\/NRR2006122"},{"key":"2015070319494900000_173.2.R47.11","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1452"},{"key":"2015070319494900000_173.2.R47.12","doi-asserted-by":"crossref","unstructured":"Rahnema CD Crosnoe LE Kim ED . Designer steroids \u2013 over-the-counter supplements and their androgenic component: a systematic review on an increasing problem. Andrology 2015 3 150\u2013155. (doi:10.1111\/andr.307).","DOI":"10.1111\/andr.307"},{"key":"2015070319494900000_173.2.R47.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2012-090988"},{"key":"2015070319494900000_173.2.R47.14","doi-asserted-by":"crossref","unstructured":"Franke WW Berendonk B . Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clinical Chemistry 1997 43 1262\u20131279.","DOI":"10.1093\/clinchem\/43.7.1262"},{"key":"2015070319494900000_173.2.R47.15","doi-asserted-by":"publisher","DOI":"10.2165\/00007256-200434080-00003"},{"key":"2015070319494900000_173.2.R47.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60801-6"},{"key":"2015070319494900000_173.2.R47.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1579"},{"key":"2015070319494900000_173.2.R47.18","doi-asserted-by":"crossref","unstructured":"Vorona E & Nieschlag E. Sequelae of doping with anabolic steroids. In Testosterone: Action, Deficiency, Substitution, 4th edn, ch 25, pp 535\u2013546. Eds E Nieschlag, HM Behre & S Nieschlag. Cambridge: Cambridge University Press, 2012","DOI":"10.1017\/CBO9781139003353.026"},{"key":"2015070319494900000_173.2.R47.19","doi-asserted-by":"crossref","unstructured":"Pope HG Jr Wood RI Rogol A Nyberg F Bowers L Bhasin S . Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews 2014 35 341\u2013375. (doi:10.1210\/er.2013-1058).","DOI":"10.1210\/er.2013-1058"},{"key":"2015070319494900000_173.2.R47.20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0620"},{"key":"2015070319494900000_173.2.R47.21","doi-asserted-by":"publisher","DOI":"10.1159\/000199045"},{"key":"2015070319494900000_173.2.R47.22","unstructured":"Dodge T Hoagland MF . The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug and Alcohol Dependence 2010 114 100\u2013109. (doi:10.1016\/j.drupalcdep2010.11.011)."},{"key":"2015070319494900000_173.2.R47.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.03.020"},{"key":"2015070319494900000_173.2.R47.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)95385-7"},{"key":"2015070319494900000_173.2.R47.25","doi-asserted-by":"crossref","unstructured":"Nieschlag E Kumar N Sitruk-Ware R . 7\u03b1-methyl-19-nortestosterone (MENTR): the Population Council's contribution to research on male contraception and treatment of hypogonadism. Contraception 2013 87 288\u2013295. (doi:10.1016\/j.contraception.2012.08.036).","DOI":"10.1016\/j.contraception.2012.08.036"},{"key":"2015070319494900000_173.2.R47.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68614-5"},{"key":"2015070319494900000_173.2.R47.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2768"},{"key":"2015070319494900000_173.2.R47.28","doi-asserted-by":"crossref","unstructured":"Knuth UA Maniera H Nieschlag E . Anabolic steroids and semen parameters in bodybuilders. Fertility and Sterility 1989 52 1041\u20131047.","DOI":"10.1530\/acta.0.120S121"},{"key":"2015070319494900000_173.2.R47.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(01)00972-9"},{"key":"2015070319494900000_173.2.R47.30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/12.8.1706"},{"key":"2015070319494900000_173.2.R47.31","unstructured":"Boyadjiev NP Georgieva KN Massaldjieva RI Gueorguiev SI . Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. Journal of Sports Medicine and Physical Fitness 2000 40 271\u2013274."},{"key":"2015070319494900000_173.2.R47.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2011.08.005"},{"key":"2015070319494900000_173.2.R47.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2011.01142.x"},{"key":"2015070319494900000_173.2.R47.34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.1.296"},{"key":"2015070319494900000_173.2.R47.35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0435"},{"key":"2015070319494900000_173.2.R47.36","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1571::AID-CNCR26>3.0.CO;2-C"},{"key":"2015070319494900000_173.2.R47.37","unstructured":"Kirkham H Algard FT . Characteristic of an androgen\/estrogen dependent leiomyosarcoma of the ductus deferens of the Syrian hamster. I. In vivo . Cancer Research 1965 25 141\u2013146."},{"key":"2015070319494900000_173.2.R47.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206168"},{"key":"2015070319494900000_173.2.R47.39","doi-asserted-by":"publisher","DOI":"10.1177\/036354659001800417"},{"key":"2015070319494900000_173.2.R47.40","doi-asserted-by":"crossref","unstructured":"Tan RS Scally MC . Anabolic steroid-induced hypogonadism \u2013 towards a unified hypothesis of anabolic steroid action. Medical Hypotheses 2009 72 723\u2013728. (doi:10.1016\/j.mehy.2008.12.042).","DOI":"10.1016\/j.mehy.2008.12.042"},{"key":"2015070319494900000_173.2.R47.41","doi-asserted-by":"crossref","unstructured":"Coward RM Rajanahally S Kovac JR Smith RP Pastuszak AW Lipshultz LI . Anabolic steroid induced hypogonadism in young men. Journal of Urology 2013 190 2200\u20132205. (doi:10.1016\/j.juro.2013.06.010).","DOI":"10.1016\/j.juro.2013.06.010"},{"key":"2015070319494900000_173.2.R47.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(03)00365-0"},{"key":"2015070319494900000_173.2.R47.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67482-2"},{"key":"2015070319494900000_173.2.R47.44","unstructured":"Pirola I Cappelli C Delbarba A Scalvini T Agosti B Assanelli D Bonetti A Castellano M . Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism. Fertility and Sterility 2010 94 2331e1\u20132331e3. (doi:10.1016\/j.fertnstert.2010.03.042)."},{"key":"2015070319494900000_173.2.R47.45","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-819936"},{"key":"2015070319494900000_173.2.R47.46","doi-asserted-by":"crossref","unstructured":"Drakeley A Gazvani R Lewis-Jones I . Duration of azoospermia following anabolic steroids. Fertility and Sterility 2004 81 226. (doi:10.1016\/j.fertnstert.2003.10.001).","DOI":"10.1016\/j.fertnstert.2003.10.001"},{"key":"2015070319494900000_173.2.R47.47","doi-asserted-by":"crossref","unstructured":"Corona G Baldi E Maggi M . Androgen regulation of prostate cancer: where are we now? Journal of Endocrinological Investigation 2011 34 232\u2013243. (doi:10.1007\/BF03347072).","DOI":"10.1007\/BF03347072"},{"key":"2015070319494900000_173.2.R47.48","doi-asserted-by":"crossref","unstructured":"Roberts JT Essenhigh DM . Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 1986 2 742. (doi:10.1016\/S0140-6736(86)90251-5).","DOI":"10.1016\/S0140-6736(86)90251-5"},{"key":"2015070319494900000_173.2.R47.49","doi-asserted-by":"crossref","unstructured":"Pinto F Sacco E Volpe A Gardi M Totaro A Calarco A Racioppi M Gulino G D'Addessi A Bassi PF . Doping and urologic tumors. Urologia 2010 77 92\u201399.","DOI":"10.1177\/039156031007700205"},{"key":"2015070319494900000_173.2.R47.50","doi-asserted-by":"crossref","unstructured":"Hollingworth M Harper A Hamer M . An observational study of erectile dysfunction, infertility and prostate cancer in regular cyclists: cycling for health UK study. Journal of Men's Health 2014 11 75\u201379.","DOI":"10.1089\/jomh.2014.0012"},{"key":"2015070319494900000_173.2.R47.51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2591"},{"key":"2015070319494900000_173.2.R47.52","doi-asserted-by":"publisher","DOI":"10.1159\/000335209"},{"key":"2015070319494900000_173.2.R47.53","doi-asserted-by":"crossref","unstructured":"Roupas ND Georgopoulos NA . Menstrual function in sports. Hormones 2011 10 104\u2013116. (doi:10.14310\/horm.2002.1300).","DOI":"10.14310\/horm.2002.1300"},{"key":"2015070319494900000_173.2.R47.54","unstructured":"Orio F Muscogiuri G Ascione A Marciano F Volpe A La Sala G Savastano S Colao A Palomba S . Effects of physical exercise on the female reproductive system. Minerva Endocrinologica 2013 38 305\u2013319."},{"key":"2015070319494900000_173.2.R47.55","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep337"},{"key":"2015070319494900000_173.2.R47.56","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000235704.45652.0b"},{"key":"2015070319494900000_173.2.R47.57","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1391"},{"key":"2015070319494900000_173.2.R47.58","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1700003"},{"key":"2015070319494900000_173.2.R47.59","doi-asserted-by":"crossref","unstructured":"Thein-Nissenbaum J . Long term consequences of the female athlete triad. Maturitas 2013 75 107\u2013112. (doi:10.1016\/j.maturitas.2013.02.010).","DOI":"10.1016\/j.maturitas.2013.02.010"},{"key":"2015070319494900000_173.2.R47.60","doi-asserted-by":"crossref","unstructured":"De Souza MJ Nattiv A Misra M Williams NI Mallinson RJ Gibbs JC Olmsted M Goolsby M Matheson G Barrack M . 2014 female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad. Current Sports Medicine Reports 2014 13 219\u2013232. (doi:10.1249\/JSR.0000000000000077).","DOI":"10.1249\/JSR.0000000000000077"},{"key":"2015070319494900000_173.2.R47.61","doi-asserted-by":"crossref","unstructured":"Van Staa TP Sprafka JM . Study of adverse outcomes in women using testosterone therapy. Maturitas 2009 62 76\u201380. (doi:10.1016\/j.maturitas.2008.11.001).","DOI":"10.1016\/j.maturitas.2008.11.001"},{"key":"2015070319494900000_173.2.R47.62","doi-asserted-by":"crossref","unstructured":"Davis SR. Testosterone use in women. In Testosterone: Action, Deficiency, Substitution, 4th edn, ch 23, pp 494\u2013516. Eds E Nieschlag, HM Behre & S Nieschlag. Cambridge: Cambridge University Press, 2012","DOI":"10.1017\/CBO9781139003353.024"},{"key":"2015070319494900000_173.2.R47.63","doi-asserted-by":"crossref","unstructured":"Urman B Pride SM Yuen BH . Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstetrics and Gynecology 1991 77 595\u2013598.","DOI":"10.1016\/0378-5122(91)90178-S"},{"key":"2015070319494900000_173.2.R47.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.01.118"},{"key":"2015070319494900000_173.2.R47.65","doi-asserted-by":"crossref","unstructured":"Walker J Adams B . Cutaneous manifestations of anabolic\u2013androgenic steroid use in athletes. International Journal of Dermatology 2009 48 1044\u20131048. (doi:10.1111\/j.1365-4632.2009.04139.x).","DOI":"10.1111\/j.1365-4632.2009.04139.x"},{"key":"2015070319494900000_173.2.R47.66","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-21-11-1440"},{"key":"2015070319494900000_173.2.R47.67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03347.x"},{"key":"2015070319494900000_173.2.R47.68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03350430083032"},{"key":"2015070319494900000_173.2.R47.69","doi-asserted-by":"publisher","DOI":"10.1016\/S0892-1997(99)80005-8"},{"key":"2015070319494900000_173.2.R47.70","unstructured":"Wollina U Pabst F Sch\u00f6nlebe J Abdel-Naser MB Konrad H Gruner M Haroske G Klemm E Schreiber G . Side-effects of topical androgenic and anabolic substances and steroids. A short review. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica 2007 16 117\u2013122."},{"key":"2015070319494900000_173.2.R47.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0633-z"},{"key":"2015070319494900000_173.2.R47.72","unstructured":"Zagouri F Sergentanis TN Tsigginou A Dimitrakakis C Zografos GC Dimopoulos MA Psaltopoulou T . Female breast cancer in Europe: statistics, diagnosis and treatment modalities. Journal of Thoracic Disease 2014 6 589\u2013590. (doi:10.3978\/j.issn.2072-1439.2014.06.18)."},{"key":"2015070319494900000_173.2.R47.73","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0310"},{"key":"2015070319494900000_173.2.R47.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2011.05.007"},{"key":"2015070319494900000_173.2.R47.75","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2260"},{"key":"2015070319494900000_173.2.R47.76","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1809"},{"key":"2015070319494900000_173.2.R47.77","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0289"},{"key":"2015070319494900000_173.2.R47.78","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(03)00033-X"},{"key":"2015070319494900000_173.2.R47.79","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0016"},{"key":"2015070319494900000_173.2.R47.80","doi-asserted-by":"crossref","unstructured":"De Gooyer ME Oppers-Tiemissen HM Leysen D Verheul HA Kloosterboer HJ . Tibolone is not converted by human aromatase to 7alpha-ethynylestradiol (7\u03b1-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC\u2013MSMS. Steroids 2008 68 235\u2013243. (doi:10.1016\/S0039-128X(02)00184-8).","DOI":"10.1016\/S0039-128X(02)00184-8"},{"key":"2015070319494900000_173.2.R47.81","unstructured":"Kley HK. Anabole Steroide \u2013 pharmakologische Wirkung der Dopingmittel. In Doping und seine Wirkstoffe.Verbotene Arzneimittel im Sport, pp 64\u201384. Ed D Clasing. Spitta Verlag, 2004"},{"key":"2015070319494900000_173.2.R47.82","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701"},{"key":"2015070319494900000_173.2.R47.83","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6"},{"key":"2015070319494900000_173.2.R47.84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14065-2"},{"key":"2015070319494900000_173.2.R47.85","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000232033.92411.51"},{"key":"2015070319494900000_173.2.R47.86","doi-asserted-by":"crossref","unstructured":"Glaser RL Dimitrakakis C . Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas 2013 76 342\u2013349. (doi:10.1016\/j.maturitas.2013.08.002).","DOI":"10.1016\/j.maturitas.2013.08.002"},{"key":"2015070319494900000_173.2.R47.87","doi-asserted-by":"publisher","DOI":"10.1210\/en.140.1.416"},{"key":"2015070319494900000_173.2.R47.88","doi-asserted-by":"publisher","DOI":"10.1096\/fj.99-0863com"},{"key":"2015070319494900000_173.2.R47.89","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(02)00105-3"},{"key":"2015070319494900000_173.2.R47.90","doi-asserted-by":"publisher","DOI":"10.1080\/713603030"},{"key":"2015070319494900000_173.2.R47.91","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000119983.48235.D3"},{"key":"2015070319494900000_173.2.R47.92","doi-asserted-by":"crossref","unstructured":"Van Winkle W . The action of steroid hormones in mammary cancer. Radiology 1949 53 530\u201353991. (doi:10.1148\/53.4.530).","DOI":"10.1148\/53.4.530"},{"key":"2015070319494900000_173.2.R47.93","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-961807"},{"key":"2015070319494900000_173.2.R47.94","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.31.1.54"},{"key":"2015070319494900000_173.2.R47.95","doi-asserted-by":"crossref","unstructured":"Gerber PA Kukova G Meller S Neumann NJ Homey B . The dire consequences of doping. Lancet 2008 372 656. (doi:10.1016\/S0140-6736(08)61278-7).","DOI":"10.1016\/S0140-6736(08)61278-7"},{"key":"2015070319494900000_173.2.R47.96","doi-asserted-by":"publisher","DOI":"10.1249\/01.mss.0000210194.56834.5d"},{"key":"2015070319494900000_173.2.R47.97","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-387"},{"key":"2015070319494900000_173.2.R47.98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607043350101"},{"key":"2015070319494900000_173.2.R47.99","unstructured":"Hoffman JR Ratamess NA . Medical issues associated with anabolic steroid use: are they exaggerated? Journal of Sports Science & Medicine 2006 5 182\u2013193."},{"key":"2015070319494900000_173.2.R47.100","doi-asserted-by":"crossref","unstructured":"Kersey RD Elliot DL Goldberg L Kanayama G Leone JE Pavlovich M Pope HG Jr National Athletic Trainers' Association . National Athletic Trainers' Association position statement: anabolic-androgenic steroids. Journal of Athletic Training 2012 47 567\u2013588.","DOI":"10.4085\/1062-6050-47.5.08"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/173\/2\/R47.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/173\/2\/R47.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:32:28Z","timestamp":1676392348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/173\/2\/R47\/6668075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":100,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-0080","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}